用于术前预测弥漫性胶质瘤IDH突变状态和WHO分级的临床-影像组学分析的开发与验证:一项使用两台PET扫描仪的连续L-[甲基-11C]蛋氨酸队列研究
本研究回顾性纳入178例术前[11C]MET PET/CT图像,用PET扫描仪1的106例构建训练集、扫描仪2的72例作验证集,建立影像组学模型并整合临床特征构建列线图。联合PET/CT影像组学模型与IDH基因型显著相关,列线图预测IDH的AUC在训练集为0.880、验证集为0.866;在IDH野生型患者中区分WHO IV级与II/III级的AUC训练集0.820、验证集0.766。
要点
- 联合[11C]MET PET/CT影像组学模型与IDH基因型显著相关,训练集和验证集均p<0.0001。
- 整合影像组学评分、年龄和肿瘤位置状态的列线图预测IDH的AUC训练集0.880、验证集0.866。
- IDH野生型中区分WHO IV级与II/III级的AUC训练集0.820、验证集0.766。
核心结论
- [11C]MET PET影像组学特征有助于无创预测IDH基因型,整合CT影像组学特征可提升效能。
- 影像组学与临床特征整合可建立用于临床应用的满意列线图。
- 基于两台PET扫描仪连续队列的无创预测研究为观察影像组学在未治疗弥漫性胶质瘤中的差异效能和稳定性提供了视角。
研究设计与样本
- 回顾性研究连续纳入178例术前[11C]MET PET/CT图像进行影像组学分析。
- 来自PET扫描仪1的106例患者作为训练数据集,来自PET扫描仪2的72例患者作为验证数据集。
- 分别提取[11C]MET PET和整合CT影像组学特征,基于PET特征、CT特征及联合PET/CT特征分别构建三个独立预测模型。
- 采用SelectKBest方法、Spearman相关分析、LASSO回归和机器学习算法进行特征选择和模型构建。
- 筛选满意预测模型后整合关键临床特征建立列线图。
主要发现
- 联合[11C]MET PET/CT影像组学模型由四个PET特征和八个整合CT特征组成,与IDH基因型显著相关,训练集和验证集均p<0.0001。
- 基于[11C]MET PET/CT影像组学评分、患者年龄和二分类肿瘤位置状态的列线图显示满意区分能力,训练集AUC为0.880(95%CI 0.726-0.998),验证集AUC为0.866(95%CI 0.777-0.956)。
- 在IDH分层WHO分级预测中,最终影像组学模型由四个PET特征和两个CT特征组成,在IDH野生型患者中对WHO II和III级与IV级患者具有合理且稳定的鉴别效能,训练集AUC为0.820(95%CI 0.541-1.000),验证集AUC为0.766(95%CI 0.612-0.921)。
关键数值与推荐
- 联合[11C]MET PET/CT影像组学模型与IDH基因型相关,训练集和验证集均p<0.0001。
- 列线图预测IDH的AUC训练集0.880(95%CI 0.726-0.998),验证集0.866(95%CI 0.777-0.956)。
- IDH野生型中区分WHO IV级与II/III级的AUC训练集0.820(95%CI 0.541-1.000),验证集0.766(95%CI 0.612-0.921)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Determination of isocitrate dehydrogenase (IDH) genotype is crucial in the stratification of diagnosis and prognostication in diffuse gliomas. We sought to build and validate radiomics models and clinical features incorporated nomogram for preoperative prediction of IDH mutation status and WHO grade of diffuse gliomas with L-[methyl-11C] methionine ([11C]MET) PET/CT imaging according to the 2016 WHO classification of tumors of the central nervous system. METHODS: Consecutive 178 preoperative [11C]MET PET/CT images were retrospectively studied for radiomics analysis. One hundred six patients from PET scanner 1 were used as training dataset, and 72 patients from PET scanner 2 were used for validation dataset. [11C]MET PET and integrated CT radiomics features were extracted, respectively; three independent predictive models were built based on PET features, CT features, and combined PET/CT features, respectively. The SelectKBest method, Spearman correlation analysis, Least Absolute Shrinkage and Selection Operator (LASSO) regression, and machine learning algorithms were applied for feature selection and model building. After filtering the satisfactory predictive model, key clinical features were incorporated for the nomogram establishment. RESULTS: The combined [11C]MET PET/CT radiomics model, which consisted of four PET features and eight integrated CT features, was significantly associated with IDH genotype (p < 0.0001 for both training and validation datasets). Nomogram based on the [11C]MET PET/CT radiomics score, patients' age, and dichotomous tumor location status showed satisfactory discrimination capacity, and the AUC was 0.880 (95% CI, 0.726-0.998) in the training dataset and 0.866 (95% CI, 0.777-0.956) in the validation dataset. In IDH stratified WHO grade prediction, the final radiomics model consists of four PET features and two CT features had reasonable and stable differential efficacy of WHO grade II and III patients from grade IV patients in IDH-wildtype patients, and the AUC was 0.820 (95% CI, 0.541-1.000) in the training dataset and 0.766 (95% CI, 0.612-0.921) in the validation dataset. CONCLUSION: [11C]MET PET radiomics features could benefit non-invasive IDH genotype prediction, and integrated CT radiomics features could enhance the efficacy. Radiomics and clinical features incorporation could establish satisfactory nomogram for clinical application. This non-invasive predictive investigation based on our consecutive cohort from two PET scanners could provide the perspective to observe the differential efficacy and the stability of radiomics-based investigation in untreated diffuse gliomas.
引用
- Zhou W, Wen J, Huang Q, et al. Development and validation of clinical-radiomics analysis for preoperative prediction of IDH mutation status and WHO grade in diffuse gliomas: a consecutive L-[methyl-11C] methionine cohort study with two PET scanners. Eur J Nucl Med Mol Imaging. 2023. PMID: 38110710. doi:10.1007/s00259-023-06562-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。